Ivermectin and filariasis

Fundamental and Clinical Pharmacology

Volumn 17, Issue 2, 2003, Pages 199-203

  Richard Lenoble, Dominique ^a   Chandenier, Jacques ^a   Gaxotte, Philippe ^b  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b NONE   (France)

Author keywords

Cutaneous larva migrans; Elephantiasis; Human filariasis; Ivermectin; Loiasis; Mansonelliasis; Nematodes; Onchocerciasis

Indexed keywords

ABAMECTIN; ALBENDAZOLE; DIETHYLCARBAMAZINE; IVERMECTIN;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; ELEPHANTIASIS; ENDEMIC DISEASE; FILARIASIS; HUMAN; INFECTION CONTROL; LARVA MIGRANS; MICROFILARIA; NEMATODE; NEUROTRANSMITTER RELEASE; ONCHOCERCIASIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT INDICATION;

CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FILARICIDES; HUMANS; IVERMECTIN; ONCHOCERCIASIS; PREGNANCY;

EID: 0037399170     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00170.x     Document Type: Article

References (13)

1. Aziz M.A., Diallo S., Diop IM., Lariviére M., Porta M. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet (1982) 1 171-173.
2. Karen L, Goa. Donna McTavish et Stephen P. Clissold. Ivermectine: Activité antifilarienne, propriétés pharmacocinétiques et efficacité clinique dans l'onchocercose. Drugs (1991) 42 640-658.
3. Richard-Lenoble D., Al Qubati Y., Pisella P.J., Toe L., Gaxotte P. Onchocercoses humaines et "Sowda" en République du Yémen. Bull. Acad. Natle, Méd. (2001) 185 1447-1461.
4. Horton J., Witt C., Ottesen E.A. et al. An analysis of the safety of single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology (2000) 121 147-160.
5. Ottesen E.A., Vijayasekaran V., Kumaraswami V. et al. Acontrolled trial of ivermectin and diethylcarbamazine in lymphatic filariasis. N. Engl. J. Med. (1990) 322 1113-1117.
6. Roux J., Perolat P.H., Cartel J.-L. et al. Etude de l'ivermectine pour le traitement de la filariose lymphatique due à Wuchereria bancrofti var. pacifica en Polynésie française. Bull. Soc. Path. Exot. (1989) 82 72-81.
7. Richard-Lenoble D., Kombila M., Rupp E. et al. Ivermectin in loiasis and concomitant O. volvulus and M. perstans infections. Am. J. Trop. Med. Hyg. (1988) 36 480-483.
8. Duong T.H., Kombila M., Ferrer A., Bureau P., Gaxotte P., Richard-Lenoble D. Reduced Loa loa microfilaria count ten to twelve months after a single dose of ivermectin. Trans. R. Soc. Trop. Med. Hyg. (1997) 91, 592-000.
9. Duong T.H., Kombila M., Ferrer A., Nguiri C., Richard-Lenoble D. Decrease in Mansonella perstans microfilaremia after albendazole treatment. Trans. R. Soc. Trop. Med. Hyg. (1998) 92 459-000.
10. Kombila M., Duong T.H., Ferrer A. et al. Short and long term action of multiple doses of ivermectin on loiasis microfilaremia. Am. J. Trop. Med. Hyg. (1998) 58, 458-460.
11. Kombila M., Duong T.H., Richard-Lenoble D. Safety of ivermectin for treating onchocerciasis in populations where loiasis is co-endemic (Central Africa:Gabon). Am. J. Trop. Med. Hyg. (1995) 53 260-261.
12. Chippaux J.P., Boussinesq M., Gardon J., Gardon-Wendel N., Ernould J.C. Severe adverse reaction risks during mass treatment with ivermectin in loiasis-endemic areas. Parasitol. Today (1996) 12 448-450.
13. o en médecine humaine hors onchocercose. Cahiers Santé (1998) 8 84-87.